The answer so far

A slower or steady weight does not by itself mean semaglutide or tirzepatide has stopped working. Weight changes can slow for several reasons, and maintaining a lower weight may be an important outcome. A brief pause is not the same as a lasting pattern; a care team can help interpret it alongside your health and treatment goals.23

On this page
  1. Is a few days without weight loss a plateau?
  2. Why can weight loss slow down?
  3. What did researchers call a plateau?
  4. Does a steady weight mean semaglutide stopped working?
  5. What did a tirzepatide maintenance study find?
  6. Should I change the medicine or eat much less?
  7. What is useful to discuss with my care team?
  8. What can the scale miss?
  9. Sources
Conceptual schematic. Simplified and not to scale; not a scan, microscopy image or validated simulation.

Is a few days without weight loss a plateau?

Not necessarily. Body weight can fluctuate and a brief pause does not identify a lasting pattern or its cause. Researchers use different definitions of a plateau, and there is no single agreed cut-off. If checking the scale is stressful, a care team can discuss whether and how tracking is useful. It is also possible not to lose weight in the first place; that is a different question from weight stabilising after a loss.26

Why can weight loss slow down?

As body weight changes, the energy needed to sustain the body can change too. Appetite and fullness signals, activity, sleep, other medicines, health conditions and access to food can also play a part. These influences differ between people. A plateau does not by itself reveal which factor matters, prove “metabolic damage” or establish that someone has done anything wrong. The difference between body fat and scale weight explains why a scale is only one measurement.62

What did researchers call a plateau?

In a 2025 exploratory analysis of tirzepatide trials, researchers looked at adults without type 2 diabetes who had already lost at least 5% of their starting weight and met other study criteria. They called it a plateau when weight changed by less than 5% over 12 weeks and then remained within their study definition through the end of follow-up. Someone could still be losing weight slowly under that definition. The researchers did not measure the biological cause of an individual plateau. These selected study results cannot predict when any one person’s weight will change or establish a rule for adjusting treatment.2

A pause on the scale: four different questionsA research definition describes a group; it cannot diagnose an individual.
  • A few daysNormal fluctuations can hide a longer-term trend.
  • A study plateauIn one tirzepatide analysis, less than 5% change over 12 weeks could still include slow weight loss.
  • MaintenanceHolding a lower weight can be an outcome; the scale alone cannot establish why.
  • Your next stepDiscuss the whole picture, including health, side effects and your goals, with your care team.

Does a steady weight mean semaglutide stopped working?

No. A steady lower weight could reflect continued benefit, although the scale alone cannot tell whether treatment is helping a particular person. In the sponsor-funded STEP 5 trial, 304 adults without diabetes were assigned semaglutide or placebo alongside behavioural support. The semaglutide group’s average change from starting weight was −15.6% at week 52 and −15.2% at week 104; the placebo group’s average change at week 104 was −2.6%. Group averages are not individual forecasts, and the trial does not show that every participant maintained weight or gained other health benefits.3

What did a tirzepatide maintenance study find?

In the sponsor-funded 2026 SURMOUNT-MAINTAIN trial, 441 adults without diabetes began a tirzepatide treatment period. After 60 weeks, 378 who had lost at least 5% of their starting weight and tolerated a specified study amount were randomly assigned to continue their prior amount, receive a lower amount, or switch to placebo for a further year. Estimated mean changes from original starting weight at the end were −21.9%, −16.6% and −9.9%, respectively. Some participants who regained substantial weight could receive rescue treatment, and the analysis used a specified method to handle those data. Most, not all, had met the study’s plateau definition before randomisation. This selected trial does not tell an individual which treatment or amount is right for them.14

Should I change the medicine or eat much less?

An unchanging scale is not a reason to increase, combine, stop or restart a medicine independently. Product instructions, side effects, the reason for treatment and other medicines matter; ask the prescriber about any change. Equally, eating substantially less can make it harder to obtain enough nutrients, especially if nausea already limits intake. There is no evidence from these studies that a particular restrictive diet or supplement is needed to “break” a plateau. For practical food and fluid questions, see eating with semaglutide or tirzepatide.57

What is useful to discuss with my care team?

Bring the name and formulation of your product, treatment history, changes in weight over time if available, side effects, other medicines and the outcomes you care about. The discussion might also include sleep, activity, eating enough, affordability and any relevant health conditions, without assuming a single cause. If the medicine is used for diabetes or another condition, glucose or other treatment goals remain part of the conversation. Ask what changes, monitoring or support may be appropriate for your circumstances.25

What can the scale miss?

The scale does not identify changes in fat, lean tissue, strength, symptoms or glucose control. A person may value physical function or management of a health condition as well as weight, although a stable weight does not guarantee any particular benefit. For the evidence, read weight-loss medicines and muscle and the tirzepatide body-scan study. If considering stopping, see what withdrawal trials found.34

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. Tirzepatide for maintenance of bodyweight reduction in people with obesity: SURMOUNT-MAINTAINThe Lancet / PubMed · Primary randomized trial publication recordAccess checked 2026-11-06 · Source date: 2026 · Indexed publication and abstract; manufacturer-funded trial in selected responders. Direct retrieval returned no substantive text during this check; indexed record was consulted.
  2. Time to weight plateau with tirzepatide in SURMOUNT-1 and SURMOUNT-4Clinical Obesity / Wiley · Sponsor-funded exploratory post-hoc trial analysis; 2025Access checked 2026-11-05 · Selected participants without type 2 diabetes, initial ≥5% loss and additional treatment criteria; retrospective study definition, not an individual diagnostic threshold.
  3. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5Nature Medicine / PubMed Central · Sponsor-funded randomised placebo-controlled trial; 2022Access checked 2026-11-05 · 304 adults without diabetes; group means during 104 weeks; behavioural support in both groups. Novo Nordisk designed and funded the trial.
  4. Tirzepatide for maintenance of bodyweight reduction: SURMOUNT-MAINTAINThe Lancet / third-party hosted publisher PDF · Sponsor-funded randomised maintenance trial; United States; 2026Access checked 2026-11-05 · 441 began open-label treatment; 378 selected responders randomised after 60 weeks; no diabetes; rescue therapy and modelled handling affect interpretation. Sponsor Lilly involved in design, analysis and drafting.
  5. Prescription medications to treat overweight and obesityNational Institute of Diabetes and Digestive and Kidney Diseases · US public-health guidanceAccess checked 2026-11-05 · General guidance on longer-term treatment; not an individual recommendation.
  6. Overweight and obesity in adultsNational Institutes of Health · US public-health overviewAccess checked 2026-11-05 · General discussion of weight management and changes over time; not a trial of either product.
  7. Zepbound tirzepatide injection: US prescribing informationDailyMed / US Food and Drug Administration · US product label, revised April 2026Access checked 2026-11-05 · Trial rates describe pooled US Zepbound groups, not individual risk or a comparison with semaglutide.

The next useful question.

Substance profile

Semaglutide.

A plain-language guide to semaglutide: one peptide medicine, different products, different authorised uses, and evidence that should not be mixed together.

10 min read
Substance profile

Tirzepatide.

A plain-language guide to what tirzepatide is, how GIP and GLP-1 signals fit together, what human trials measured, and what remains uncertain.

12 min read